Zhang Feng, Gong Weihong
Department of Oncology, Linyi People's Hospital, Linyi, China.
Department of Comprehensive Intervention, Linyi People's Hospital, Linyi, China.
Front Oncol. 2020 Jul 28;10:1116. doi: 10.3389/fonc.2020.01116. eCollection 2020.
The prognostic role of the platelet-to-lymphocyte ratio (PLR) is controversial in patients with melanoma. Therefore, we performed a meta-analysis to assess the prognostic value of the PLR in patients with melanoma. PubMed, Web of Science, Embase, Cochrane library, WanFang, and China National Knowledge Infrastructure were searched for eligible studies. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the association between the PLR and overall survival (OS) and progression-free survival (PFS). Nine studies with 2,396 patients were included in this meta-analysis. A high PLR was a predictor of shorter OS (HR = 1.67, 95% CI = 1.18-2.38, = 0.004), but not PFS (HR = 1.53, 95% CI = 0.96-2.44, = 0.075) in patients with melanoma. Subgroup analysis revealed that the PLR remained a significant prognostic indicator of both OS and PFS in patients with non-metastatic disease; the PLR cutoff value of <120 had a consistent prognostic value. An increased PLR was associated with poor OS of patients with melanoma. Hence, we suggest that the preoperative PLR could be used to identify high-risk patients and provide information regarding the prognosis of patients with melanoma.
血小板与淋巴细胞比值（PLR）在黑色素瘤患者中的预后作用存在争议。因此，我们进行了一项荟萃分析，以评估PLR在黑色素瘤患者中的预后价值。检索了PubMed、Web of Science、Embase、Cochrane图书馆、万方和中国知网，查找符合条件的研究。计算合并风险比（HRs）和95%置信区间（CIs），以评估PLR与总生存期（OS）和无进展生存期（PFS）之间的关联。本荟萃分析纳入了9项研究，共2396例患者。在黑色素瘤患者中，高PLR是OS较短的预测指标（HR = 1.67，95% CI = 1.18 - 2.38，P = 0.004），但不是PFS的预测指标（HR = 1.53，95% CI = 0.96 - 2.44，P = 0.075）。亚组分析显示，在非转移性疾病患者中，PLR仍然是OS和PFS的重要预后指标；PLR临界值<120具有一致的预后价值。PLR升高与黑色素瘤患者的OS较差相关。因此，我们建议术前PLR可用于识别高危患者，并提供有关黑色素瘤患者预后的信息。
